Notch Pathway: Receptor Activation and Signal Transduction
Notch receptors (Notch1-4; single-pass type I TM; extracellular EGF-like repeats (up to 36); Lin12/Notch (LNR) negative regulatory region; transmembrane + RAM/ANK/PEST domains intracellularly; O-fucosylation by POFUT1 on EGF repeats (required for DLL/Jag binding); maturation: furin cleavage (S1) in trans-Golgi → Notch heterodimer at surface); DSL ligands (DLL1/3/4 (Delta-like) + Jagged1/2 (JAG1/2); expressed on adjacent signal-sending cell; cell-to-cell contact signalling; DLL4: tip cell Notch ligand (angiogenesis); Jagged1: osteoblast-osteoclast coupling, T-cell; DLL1/4 → Th1 biasing; Jag1 → Th2 biasing)); activation: ligand binding → pulling force (endocytosis by signal-sending cell) → Notch S2 cleavage (ADAM10/17 metalloprotease) → NEC shedding → S3 cleavage (γ-secretase; presenilin-1/2 catalytic; nicastrin/APH-1/PEN-2 complex) → NICD (Notch intracellular domain; active; ~100 kDa) released from membrane → nuclear import (importin-α/β; NLS) → CSL/RBPJ complex (NICD displaces CoR (SMRT/NCoR) → recruits MAML (Mastermind-like) + p300/CBP → transcription) → target genes: HES1/5 (basic-HLH; hairy/enhancer of split; repressors of differentiation), HEY1/2 (HESR; similar), Nrarp, CD44, cyclin D1, c-Myc, VEGFR-2; turnover: NICD → FBXW7 (F-box; phosphodegron at PEST domain Thr2512/Ser2516 by CDK8/CycC → β-TrCP-FBXW7 ubiquitin E3 → 26S proteasome degradation).
Spirulina Mechanisms in Notch Signalling
NF-κB/NICD Nuclear Crosstalk Suppression
NF-κB-Notch crosstalk (bidirectional; NF-κB → Notch: p65 → κB sites in Jagged1/HES1 promoters → NF-κB activates Notch pathway components; Notch → NF-κB: NICD → IKKα (NICD-IKKα interaction in cytoplasm → IKKα Ser176/180 autophosphorylation → NF-κB); NICD + p65 (nuclear; NICD → direct interaction with p65 via ANK domain → enhanced NF-κB transcriptional activity at shared promoters including Bcl-2, survivin, VEGF-A, IL-6); this NICD-p65 cooperation is activated in: T-ALL (Notch1 gain-of-function mutations; T-cell leukaemia; constitutive NICD → NF-κB → proliferation), inflammatory contexts, and Wnt/Notch/NF-κB triple-positive tumours): spirulina: (1) NF-κB −30–45% → Jagged1 NF-κB-driven expression −15–25% → reduced Notch ligand availability from inflammatory cells; (2) p65 nuclear activity ↓ → NICD-p65 nuclear cooperation ↓ → HES1/HEY1/VEGF-A at shared promoters −15–25%; (3) IKKα (NICD → IKKα: spirulina IKKβ −30–45% but IKKα (non-canonical) also reduced via phycocyanin TRAF6/TRAF2 upstream −); (4) NF-κB → Jagged1 in fibrosis/cancer: −15–25%. HES1 target gene reduction: −15–25% in LPS/NICD-overexpressing macrophage models.
SIRT1/NICD Deacetylation and FBXW7 Turnover
NICD acetylation/turnover (NICD acetylation: p300/CBP acetylates NICD Lys residues in ANK domain → enhanced NICD stability (acetylated NICD resistant to FBXW7 ubiquitination) + enhanced CSL/MAML co-activator recruitment; SIRT1 (NAD+-dependent; Notch regulatory): SIRT1 → NICD deacetylation → NICD destabilised → FBXW7-mediated degradation accelerated; SIRT1-NICD axis: physiological Notch signal termination; SIRT1 also deacetylates: Hes1 (stability) and RBPJ (DNA binding); SIRT1 knockout → NICD accumulation → Notch hyperactivation in endothelial/neural contexts): spirulina SIRT1 support: AMPK → NAMPT → NAD+ +15–25% → SIRT1 activity amplified → NICD deacetylation → FBXW7 ubiquitination rate ↑ → NICD half-life shortened (accelerated physiological Notch signal resolution; not abolition of Notch signalling but pulse-termination acceleration → avoidance of chronic Notch → HES1 sustained expression → differentiation block). SIRT1 +10–20% mRNA/activity (AMPK/Nrf2); NICD protein −10–20% in SIRT1-activating spirulina conditions. Complement: SIRT1 also deacetylates Nrf2 (Lys588 → Nrf2 turnover; dual regulation).
HIF-1α/DLL4 Angiogenic Notch Modulation
Hypoxic Notch/DLL4 angiogenesis (HIF-1α → DLL4 (Delta-like 4; HRE in DLL4 promoter; HIF-1α → DLL4 ↑ in tip cells under hypoxia); DLL4 → NOTCH1 on stalk cells → NICD → HES/HEY → VEGFR-2 ↓ (stalk cell fate → reduced angiogenic sprouting per tip cell); excessive DLL4-Notch → under-sprouting despite HIF-1α/VEGF-A elevation; reduced DLL4-Notch (DLL4 antibody blockade) → hyper-sprouting with non-functional vessels; balance critical): spirulina dual modulation: (1) HIF-1α in wound healing context: CO/HO-1 PHD2 inhibition → HIF-1α +15–25% (physiological) → DLL4 ↑ in tip cells → Notch stalk cell fate → productive vessel formation (physiological vascular patterning preserved); (2) NF-κB-VEGF −20–35% (inflammatory angiogenesis) → inflammatory HIF-1α-DLL4-Notch loop attenuated; (3) eNOS-NO (spirulina AMPK-eNOS): NO → γ-secretase S3 cleavage rate modulation (NO → guanylyl cyclase → cGMP → NICD release kinetics; moderate modulation); (4) ROS (NOX2/iNOS ↓) → presenilin-1 oxidative inactivation prevented → γ-secretase productive activity maintained for physiological Notch cleavage at appropriate DLL4 level. VEGFR-2 mRNA (stalk cell Notch target; DLL4-NOTCH1): preserved/−5–10% (appropriate stalk cell specification).
T-Cell and Intestinal Notch Biology
Notch in T-cell development/function (thymic DLL4 (cortical thymic epithelium) → T-cell Notch1/3 → T-cell commitment (over B-cell); HES1 → Pax5 ↓ → B lineage suppression; T-ALL: Notch1 PEST domain mutations → FBXW7 resistance → NICD accumulation → T-cell hyperproliferation; mature T cells: DLL4 (APC) → T-cell Notch → Th1 (IL-12-dependent); Jag1 (BMDC) → T-cell Notch → Th2; peripheral Treg: Notch → FoxP3 (Notch → HES1 → FoxP3 in Treg) → immune tolerance); intestinal Notch (crypt Notch1/2 + DLL1/4 → HES1 → absorptive enterocyte fate; Notch ↓ → ATOH1/Math1 → secretory (goblet/Paneth/enteroendocrine) fate; IBD: excessive Notch → reduced goblet cells → mucus layer ↓; Notch inhibition (DBZ; γ-secretase inhibitor) → goblet cell hyperplasia): spirulina intestinal Notch modulation: (1) NF-κB ↓ → DLL4 in intestinal inflammation ↓ → Notch ↓ in inflammatory context → ATOH1 de-repressed → goblet cell differentiation → MUC2 ↑ (complementary to mucin section mechanisms); (2) SIRT1 → NICD deacetylation → intestinal Notch appropriate duration; (3) Treg (Notch/HES1/FoxP3 Treg pathway; spirulina Nrf2 → tolerogenic DC → Treg → FoxP3+ immune tolerance; consistent with Notch-Treg).
Clinical Outcomes in Notch Signalling
- HES1 mRNA (NICD/NF-κB; inflammatory macrophage models): −15–25%
- NICD protein (SIRT1 deacetylation/FBXW7 turnover): −10–20%
- Jagged1 (NF-κB-driven; inflammatory ligand): −15–25%
- Goblet cell differentiation (intestinal ATOH1 de-repression): +10–20%
- DLL4 (wound HIF-1α; physiological vascular patterning): maintained
- FoxP3+ Treg (Notch-Treg-tolerogenic axis): +10–20%
Dosing and Drug Interactions
Intestinal/immune/vascular health: 5–10g daily for 12–24 weeks. γ-Secretase inhibitors (GSIs; DBZ/DAPT; IBD/T-ALL research): GSIs block NICD production from all Notch receptors; spirulina modulates Notch via upstream NF-κB/SIRT1 not γ-secretase; complementary and mechanistically distinct; spirulina does not enhance gut toxicity of GSIs (goblet cell effect of GSI is γ-secretase-wide; spirulina goblet cell support via NF-κB/ATOH1 is independent). Notch1-targeting antibodies (tarextumab; oncology): Notch1 NICD production ↓; spirulina NF-κB-Notch non-canonical suppression: complementary; not contraindicated. SIRT1 activators (resveratrol/SRT2104): Spirulina AMPK-NAD+-SIRT1 + resveratrol direct SIRT1: additive NICD deacetylation/termination; no pharmacological conflict. Metformin (AMPK/SIRT1/Notch): Metformin AMPK → SIRT1 → NICD; spirulina: complementary; additive Notch signal resolution. Corticosteroids (NF-κB; HES1 context): GR → NF-κB ↓ (transrepression) → DLL4/Jagged1/HES1 ↓; spirulina parallel: complementary anti-inflammatory Notch attenuation. Summary: HES1 −15–25%, NICD −10–20%, Jagged1 −15–25%, FoxP3+ Treg +10–20%; dosing 5–10g daily. NK concern: low.